Plexxikon Inc.

Plexxikon Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary of Daiichi Sankyo Company, Limited, which may influence its climate commitments and initiatives.

While Plexxikon Inc. does not report its own emissions, it inherits climate-related initiatives and targets from its parent company, Daiichi Sankyo. This includes commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are cascaded from Daiichi Sankyo. However, specific reduction targets or achievements for Plexxikon Inc. have not been disclosed.

In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and reducing their carbon footprints. Although Plexxikon Inc. has not provided specific emissions data or reduction targets, its affiliation with Daiichi Sankyo suggests a commitment to aligning with industry standards for climate action.